Skip Navigation
  Search Menu
Find an Expert

 

Tamara Levin Lotan, M.D.

Photo of Dr. Tamara Levin Lotan, M.D.

Associate Professor of Pathology

Expertise: Pathology, Prostate Cancer

Research Interests: Prostate cancer; Bladder cancer

Locations

The Johns Hopkins Hospital (Main Entrance)

1800 Orleans St. Sheikh Zayed Tower Baltimore, MD 21287 map

Phone: 410-955-9790

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue Baltimore, MD 21224 map

Phone: 410-955-9790

Johns Hopkins Outpatient Center

601 N. Caroline St. Baltimore, MD 21287 map

Phone: 410-955-9790

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

401 N. Broadway Baltimore, MD 21231 map

Phone: 410-955-9790 | Fax: 410-502-9911

Background

Dr. Tamara Lotan is an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine. Her area of clinical expertise is urologic pathology.

Dr. Lotan received her medical degree from the University of Chicago Pritzker School of Medicine. She completed her residency in anatomic pathology at the University of Chicago Hospitals and performed a fellowship in Urologic Pathology at the Johns Hopkins University School of Medicine.

She is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Her basic research focuses on the role of PTEN/PI3K/mTOR signaling in a number of epithelial systems (prostate, breast, skin), and is principally directed towards understanding how these oncogenic signaling pathways affect epithelial differentiation, cell adhesion and migration using transgenic mouse models. The translational research program in her lab has centered on the analytic, pre-analytic and clinical validation of a number of prognostic and/or predictive tissue-based biomarkers in prostate cancer. 

Dr. Lotan was recognized by the Prostate Cancer Foundation with the 2011 Elaine Wynn – PCF Young Investigator Award. She is a member of the United States and Canadian Academy of Pathology, the College of American Pathology, and the International Society of Urologic Pathology. 

Dr. Lotan is engaged in research training and is the Associate Director of the Pathobiology graduate program at Johns Hopkins.

 

...read more

Titles

  • Associate Professor of Pathology
  • Associate Professor of Oncology
  • Joint Appointment in Urology

Departments / Divisions

Education

Degrees

  • MD, University of Chicago Pritzker School of Medicine (2003)

Residencies

  • University of Chicago Medicine Mitchell Hospital-Hyde Park / Anatomic Pathology (2005)
  • University of Chicago Medicine Mitchell Hospital-Hyde Park / Anatomic Pathology (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Pathology (2008)

Board Certifications

  • American Board of Pathology / Anatomic Pathology (2007)

Research & Publications

Research Summary

Dr. Tamara Lotan is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Using novel transgenic mouse models combined with human tumor tissue samples, Dr. Lotan is defining the roles of these critical signals in epithelial development and tumor progression.

Lab

Dr. Lotan is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Her basic research focuses on the role of PTEN/PI3K/mTOR signaling in a number of epithelial systems (prostate, breast and skin), and is principally directed towards understanding how these oncogenic signaling pathways affect epithelial differentiation, cell adhesion and migration using transgenic mouse models.

The translational research program in her lab has centered on the analytic, pre-analytic and clinical validation of a number of tissue-based biomarkers in prostate cancer which are useful for molecular classification of prostate tumors and which may serve as prognostic and/or predictive biomarkers.  Her lab is best known for its work on PTEN, the most commonly lost tumor suppressor in prostate cancer and the most prevalent molecular alteration associated with patient outcomes in the disease. Working collaboratively with national and international groups, the lab completed genetic validation of this assay in more than 5000 prostate tumors, and it is now used in CLIA-accredited laboratories and routinely in clinical surgical pathology at Johns Hopkins.   In parallel, the Lotan lab has also worked on highly validated assays to assess additional tumors suppressors, including TP53, RB1 and MSH2 mutational status in prostate cancer.  The lab also has an active interest in prostate cancer health disparity research.  

Selected Publications

View all on Pubmed

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research 2011; 17(20):6563-73.

Tan H, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. Rb Loss is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research 2014; 20(4):890-903.

Ahearn TU, PetterssonA, Ebot EM, Gerke T, Morais CL, Hicks J, Wilson KM, RiderJR, Sesso HD,Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA*, Lotan TL*. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. JNCI 2016; 108(2). *Equal Contribution

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks JL, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research 2017; 23(22):6863-6874.

Asrani K, Sood A, Torres A, Georgess D, Phatak P, Kaur H, Dubin A, Talbot CC Jr, Elhelu L, Ewald AJ, Xiao B, Worley P, Lotan TL. mTORC1 Loss Impairs Epidermal Adhesion via TGF-β/Rho kinase activation. Journal of Clinical Investigation 2017; 127(11):4001-4017.

Activities & Honors

Honors

  • Elaine Wynn Young Investigator Award, PCF, 2011

Memberships

  • College of American Pathology
  • International Society of Urologic Pathology
  • United States and Canadian Academy of Pathology

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile